Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gambro breaks into Turkey through clinic purchase:

This article was originally published in Clinica

Executive Summary

Swedish company Gambro has bought the Bulten dialysis centre, as well as a local sales company, in Turkey - its first move into this market, where it immediately takes a 10-12% share of the market for dialysis products. "The acquisition is a clear signal that we intend to move into this strategically important market, a market with more patients than Spain and almost as big as France," said Lennart la Fleur, managing director of Gambro Export. Over the past few years, the Turkish dialysis market has been growing at 15% annually.

You may also be interested in...



10 Predictions On How Health Policy Could Change Under A Biden Presidency

Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.

Hologic Aptima Assay Cleared For HIV Detection

Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.

Alnylam Turns To Value-Based Pricing Again For Oxlumo

As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.

Topics

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel